Dihydroartemisinin counteracts fibrotic portal hypertension via farnesoid X receptor-dependent inhibition of hepatic stellate cell contraction.
about
Novel treatment options for portal hypertension.Hepatic stellate cells as key target in liver fibrosis.Gugulipid causes hypercholesterolemia leading to endothelial dysfunction, increased atherosclerosis, and premature death by ischemic heart disease in male mice.Artemisinin: A Panacea Eligible for Unrestrictive Use?Update on FXR Biology: Promising Therapeutic Target?
P2860
Dihydroartemisinin counteracts fibrotic portal hypertension via farnesoid X receptor-dependent inhibition of hepatic stellate cell contraction.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Dihydroartemisinin counteracts ...... tic stellate cell contraction.
@en
Dihydroartemisinin counteracts ...... tic stellate cell contraction.
@nl
type
label
Dihydroartemisinin counteracts ...... tic stellate cell contraction.
@en
Dihydroartemisinin counteracts ...... tic stellate cell contraction.
@nl
prefLabel
Dihydroartemisinin counteracts ...... tic stellate cell contraction.
@en
Dihydroartemisinin counteracts ...... tic stellate cell contraction.
@nl
P2093
P2860
P356
P1433
P1476
Dihydroartemisinin counteracts ...... tic stellate cell contraction.
@en
P2093
Chunfeng Lu
Feng Zhang
Jiangjuan Shao
Shizhong Zheng
Shunyu Yao
Wenxuan Xu
P2860
P304
P356
10.1111/FEBS.13956
P407
P577
2016-11-07T00:00:00Z